Amalgamated Bank’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q3
Sell
-12,561
Closed -$226K 1529
2020
Q2
$226K Sell
12,561
-859
-6% -$11.9K 0.01% 1243
2020
Q1
$96K Sell
13,420
-112
-0.8% -$1.4K ﹤0.01% 1498
2019
Q4
$323K Buy
13,532
+993
+8% +$27.4K 0.01% 1365
2019
Q3
$336K Buy
12,539
+531
+4% +$14.9K 0.01% 1251
2019
Q2
$326K Buy
12,008
+2,204
+22% +$69.1K 0.01% 1311
2019
Q1
$340K Buy
+9,804
New +$283K 0.01% 1185
2018
Q3
Sell
-9,890
Closed -$374K 1699
2018
Q2
$374K Buy
9,890
+2,286
+30% +$87.4K 0.01% 1184
2018
Q1
$248K Sell
7,604
-133
-2% -$5.84K 0.01% 1331
2017
Q4
$377K Buy
7,737
+712
+10% +$36K 0.01% 1140
2017
Q3
$380K Buy
7,025
+649
+10% +$38.1K 0.01% 1073
2017
Q2
$358K Buy
6,376
+328
+5% +$13.1K 0.01% 1097
2017
Q1
$237K Buy
+6,048
New +$193K 0.01% 1286
2016
Q1
Sell
-4,797
Closed -$247K 1314
2015
Q4
$247K Sell
4,797
-42
-0.9% -$2.04K 0.03% 924
2015
Q3
$206K Buy
4,839
+58
+1% +$2.8K 0.02% 1136
2015
Q2
$218K Buy
+4,781
New +$192K 0.02% 1199

Amalgamated Bank's PTLA Position: Q3 2020 in Review

Amalgamated Bank sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q3 2020, closing a stake of 12,561 shares — an estimated $226K sold.

Amalgamated Bank first reported a position in PTLA in Q2 2015 and held it in 15 quarters. The position peaked at $380K in Q3 2017. 0 funds tracked by Wall St. Rank hold PTLA as of Q3 2020.

  • Amalgamated Bank reported no remaining Portola Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
  • Amalgamated Bank sold 12,561 Portola Pharmaceuticals, Inc. shares in Q3 2020, an estimated $226K.
  • Amalgamated Bank first reported a position in Portola Pharmaceuticals, Inc. in Q2 2015 and held it in 15 quarters.
  • Amalgamated Bank's Portola Pharmaceuticals, Inc. position peaked at $380K in Q3 2017.
  • 0 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q3 2020.

Based on Amalgamated Bank's 13F filing for Q3 2020, filed 30 Oct 2020.